Sapio Maria Rosaria, Posca Daniela, Raggioli Angelo, Guerra Anna, Marotta Vincenzo, Deandrea Maurilio, Motta Manuela, Limone Paolo Piero, Troncone Giancarlo, Caleo Alessia, Rossi Guido, Fenzi Gianfranco, Vitale Mario
Department of Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II, Naples, Italy.
Clin Endocrinol (Oxf). 2007 May;66(5):678-83. doi: 10.1111/j.1365-2265.2007.02800.x. Epub 2007 Mar 23.
Fine-needle aspiration biopsy (FNAB) is the primary means to distinguish benign from malignant nodules and select patients for surgery. However, adjunctive diagnostic tests are needed because in 20-40% of cases the FNAB result is uncertain.
We investigated whether a search for the oncogenes RET/PTC, TRK and BRAF(V600E) in thyroid aspirates could refine an uncertain diagnosis.
A total of 132 thyroid aspirates, including colloid nodules, inadequate samplings, indeterminate and suspicious for malignancy were analysed by reverse transcription polymerase chain reaction (RT-PCR) and mutant allele-specific amplification techniques for the presence of oncogenes.
No oncogenes were detected in 48 colloid nodules, 46 inadequate and 19 indeterminate FNABs, then confirmed to be benign at histology. No oncogenes were detected in one follicular thyroid cancer (FTC) with indeterminate cytology. Five out of six papillary thyroid cancers (83%) with FNAB suspicious for malignancy were correctly diagnosed by the presence of oncogenes. Among these, four (67%) contained the BRAF mutation and one (17%) contained RET/PTC-3. On final analysis, no false-positive results were reported in 131 samples and five out of seven carcinomas (71%) were correctly diagnosed. The finding of oncogenes in FNAB specimens suspicious for malignancy guided the extent of surgical resection, changing the surgery from diagnostic to therapeutic in five cases.
Detection of RET/PTC, TRK and BRAF(V600E) in FNAB specimens is proposed as a diagnostic adjunctive tool in the evaluation of thyroid nodules with suspicious cytological findings.
细针穿刺活检(FNAB)是区分甲状腺结节良恶性以及选择手术患者的主要手段。然而,由于20% - 40%的病例中FNAB结果不确定,因此需要辅助诊断测试。
我们研究了在甲状腺穿刺物中检测癌基因RET/PTC、TRK和BRAF(V600E)是否能改善不确定的诊断。
通过逆转录聚合酶链反应(RT-PCR)和突变等位基因特异性扩增技术分析了总共132份甲状腺穿刺物,包括胶体结节、取样不足、不确定以及可疑恶性的样本,以检测癌基因的存在。
48个胶体结节、46个取样不足和19个不确定的FNAB样本中未检测到癌基因,这些样本经组织学证实为良性。1例细胞学不确定的滤泡状甲状腺癌(FTC)中未检测到癌基因。6例FNAB可疑恶性的乳头状甲状腺癌中有5例(83%)通过癌基因的存在被正确诊断。其中,4例(67%)含有BRAF突变,1例(17%)含有RET/PTC-3。最终分析显示,131个样本中未报告假阳性结果,7例癌中有5例(71%)被正确诊断。在可疑恶性的FNAB标本中发现癌基因指导了手术切除范围,5例手术从诊断性变为治疗性。
在FNAB标本中检测RET/PTC、TRK和BRAF(V600E)被提议作为评估细胞学结果可疑的甲状腺结节的诊断辅助工具。